|Bid||1.4650 x 0|
|Ask||1.4700 x 0|
|Day's range||1.4550 - 1.4870|
|52-week range||1.0150 - 2.4700|
|Beta (3Y monthly)||2.30|
|PE ratio (TTM)||N/A|
|Earnings date||27 May 2019 - 31 May 2019|
|Forward dividend & yield||N/A (N/A)|
|1y target est||2.87|
MELBOURNE, Australia; and NEW YORK, May 23, 2019 -- Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in cellular medicines for inflammatory diseases, will feature at the.
NEW YORK and MELBOURNE, Australia, May 17, 2019 -- Mesoblast Limited (Nasdaq: MESO; ASX: MSB), global leader in cellular medicines for inflammatory diseases, today announced an.
ASX:MSB) global leader in cellular medicines for inflammatory diseases, announced today that the United States Food and Drug Administration (FDA) has agreed that Mesoblast can submit on a rolling basis a Biologics License Application (BLA) for its allogeneic cellular medicine remestemcel-L in children with steroid-refractory acute Graft Versus Host Disease (SR-aGVHD). Mesoblast will submit each module of the BLA to the FDA on a rolling basis as it is completed. The rolling process will provide opportunity for ongoing and frequent communication, and during this process the Company expects it will be able to adequately address any substantial matters raised by the FDA.
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! Silviu Itescu became the CEO of Mesoblast Limited (ASX:MSB) in 2011. First, this article will compare CEO compensa...
NEW YORK and MELBOURNE, Australia, April 05, 2019 -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in cellular medicines for inflammatory diseases, today announced an.
ASX:MSB), global leader in cellular medicines for inflammatory diseases, today announced that the International Center for Health Outcomes and Innovation Research (InCHOIR) at the Icahn School of Medicine at Mount Sinai and Mesoblast have entered into a Memorandum of Understanding (MOU) to conduct a confirmatory clinical trial using Mesoblast’s product candidate Revascor (MPC-150-IM) for reduction of gastrointestinal (GI) bleeding in end-stage heart failure patients implanted with a left ventricular assist device (LVAD). Dr Frank Pagani, Professor, Department of Cardiac Surgery at the University of Michigan, and co-principal investigator of the recently completed 159-patient study for which InCHOIR served as the central coordinating and data management arm, said: “Gastrointestinal bleeding episodes are a major life-threatening complication of LVAD implants that occur in 20-40% of recipients in the first six months, resulting in recurrent hospitalizations and compromising quality of life.
ASX:MSB) today announced its licensee in Japan, JCR Pharmaceuticals Co. Ltd., has filed to extend marketing approval of TEMCELL®1 HS Inj. TEMCELL is already approved for the treatment of acute graft versus host disease (aGVHD), and was the first allogeneic cellular medicine to receive full regulatory approval in Japan. The parties have amended their License Agreement in order for JCR to access Mesoblast’s mesenchymal stem cell (MSC) wound healing patents to enable it to develop and commercialize TEMCELL for EB.
ASX: MSB) today announced it has appointed Joseph R. Swedish as non-executive Chairman. Mr Swedish will succeed outgoing Chairman Brian Jamieson, who is retiring from the Board on March 31, 2019. Mesoblast Chief Executive Dr Silviu Itescu said: “As Mesoblast transitions to a commercial stage company, we welcome the deep healthcare expertise of Joe Swedish in the role of Chairman. In particular his track record in healthcare resource allocation and reimbursement metrics will be a tremendous asset as we plan our first product launch in the United States.
NEW YORK and MELBOURNE, Australia, March 13, 2019 -- Mesoblast Limited (ASX: MSB; Nasdaq: MESO) today announced it will be featured at two investor conferences in March:.
Mesoblast Limited's (ASX:MSB): Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. With the latest financial year loss of -US$35.3m and a trailing-twelve month of -US$86.1m, the AU$624mRead More...
MELBOURNE, Australia and NEW YORK, Feb. 20, 2019 -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB) today reported its financial results and operational highlights for the six months.
ASX:MSB), a world leader in development and commercialization of cellular medicines, announced today that the last patient has now been dosed in the Phase 3 events-driven trial of its allogeneic cell therapy product candidate Revascor for advanced chronic heart failure. Results from a prior Phase 2 trial identified the patients most likely to benefit from Revascor as being those at high risk of recurrent hospitalization events and death.
NEW YORK and MELBOURNE, Australia, Feb. 13, 2019 -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB) will report financial results for the half year and second quarter ended December.
Nasdaq: MESO) today announced that it has drawn down a further US$15 million from its US$75 million, non-dilutive, four-year credit facility with Hercules Capital, Inc. (HTGC). The funds will be used primarily to ramp up Mesoblast’s product commercialization programs including building out a targeted sales force for its product candidate for acute graft versus host disease (aGVHD). Mesoblast plans to meet with the U.S. FDA during the first half of 2019 to discuss a potential approval pathway for Revascor having met this clinically meaningful outcome in LVAD patients.
If you're interested in Mesoblast Limited (ASX:MSB), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could impact Read More...
Nasdaq:MESO), world leader in the development and commercialization of cellular medicines, today reported on commercial and development plans for its lead cellular therapies to Biotech Showcase 2019 being held this week in San Francisco, CA. Mesoblast Chief Executive Dr Silviu Itescu said: "We enter calendar 2019 building upon the successful advancement of our late-stage pipeline where we successfully completed a Phase 3 trial in steroid-refractory acute graft versus host disease (aGVHD) which has near-term commercial potential in the United States (U.S.), and another product candidate having achieved clinical outcomes in line with the U.S. Food and Drug Administration (FDA) guidance for a registrable clinical indication for market authorization, and two additional Phase 3 assets with blockbuster potential.
ASX:MSB), world leader in development and commercialization of allogeneic (off-the-shelf) cellular medicines, today announced that it has completed patient recruitment in the events-driven Phase 3 trial of its product candidate Revascor (MPC-150-IM) for advanced chronic heart failure. Mesoblast Chief Executive Dr Silviu Itescu stated: “Completion of recruitment in this Phase 3 trial, the largest cell therapy trial for heart failure, is a key milestone for Mesoblast and has been achieved on plan.
Mesoblast will enter 2019 with the most mature cell therapy product pipeline and technology platform in the regenerative medicine industry. Two commercial products have already been approved and marketed by the Company’s licensees JCR Pharmaceuticals Co, Ltd. in Japan and Takeda Pharmaceutical Company in Europe. Mesoblast has one product candidate which has successfully completed Phase 3 and with near-term commercial potential in the United States (U.S.), another product candidate having achieved clinical outcomes in line with the U.S. Food and Drug Administration (FDA) guidance for a registrable clinical indication for market authorization, and two additional Phase 3 assets with blockbuster potential. Mesoblast’s royalty income and milestone payments from licensees continues to grow, the Company has sufficient cash to achieve key commercial milestones, and access to additional non-dilutive sources of capital from strategic financial institutions whose extensive due diligence provides further third party validation of the strength of the product portfolio and patent estate.
NEW YORK and MELBOURNE, Australia, Dec. 24, 2018 -- Mesoblast Limited (ASX:MSB; Nasdaq:MESO) will report on its Phase 3 trials and commercial plans at the upcoming Biotech.
ASX:MSB) today announced that it has appointed Eric Strati, PhD, to the new position of Senior Vice President, Commercial. Dr Strati said: “My first priority is to build a highly efficient and targeted field sales team to leverage existing relationships with transplant centers in the United States. Prior to joining Mesoblast in 2015, Dr Strati held various leadership roles in global pharmaceutical companies, most recently at Novartis where he was Executive Director, Managed Markets, and a key member of the successful launch teams for the blockbuster drugs Entresto® in chronic heart failure and Cosentyx® in moderate to severe psoriasis.
ASX:MSB) today announced that recent meetings held with the United States Food and Drug Administration (FDA) support its planned regulatory filing for commercialization of remestemcel-L in pediatric patients with steroid refractory acute graft versus host disease (aGVHD). Mesoblast gained agreement from the FDA on the proposed chemistry and manufacturing for commercialization. The FDA also provided guidance on the presentation of data from the completed 55-patient Phase 3 trial and the 241-patient Expanded Access Program to be included in the filing for the proposed indication. In the Phase 3 trial, Mesoblast met the pre-specified primary endpoint of improved Day 28 overall response and improved responder survival through Day 180.